Ticker

Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta

Aptorum Group Limited (NASDAQ: APM - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 12,292 shares, a growth of 41.4% from the March 15th total of 8,693 shares. Based on an average trading volume of 145,672 shares, the short-interest ratio

Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Risk and Volatility Aptorum Group has a

Andean Precious Metals (TSE: APM) used its fourth-quarter and year-end earnings call to highlight what management described as a "step change" in 2025 results, driven by record financial performance, strong free cash flow, and a significantly strengthened balance sheet. Executives pointed to contributions from both the San Bartolomé silver operation and the Golden Queen gold operation,

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript